INVA Stock Overview
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$16.29|
|52 Week High||US$20.71|
|52 Week Low||US$12.14|
|1 Month Change||-10.64%|
|3 Month Change||-18.51%|
|1 Year Change||23.69%|
|3 Year Change||12.27%|
|5 Year Change||33.85%|
|Change since IPO||-10.05%|
Recent News & Updates
We Think Innoviva (NASDAQ:INVA) Can Manage Its Debt With Ease
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Taking Innoviva Winnings Off The Table, Again
I think Innoviva's recent financial results have been quite good in many ways. Both revenue and net income are materially higher than both 2020 and 2019. I think Innoviva management likely overpaid for the stock buyback, but this isn't the worst thing in the world, in my view. The worst thing is the valuation here. Last month's short puts are now even deeper out of the money, and the bid has collapsed as a result. So I'm selling INVA stock and maintaining my short put position.
|INVA||US Pharmaceuticals||US Market|
Return vs Industry: INVA exceeded the US Pharmaceuticals industry which returned 10.8% over the past year.
Return vs Market: INVA exceeded the US Market which returned -12.9% over the past year.
|INVA Average Weekly Movement||5.1%|
|Pharmaceuticals Industry Average Movement||11.7%|
|Market Average Movement||7.9%|
|10% most volatile stocks in US Market||16.9%|
|10% least volatile stocks in US Market||3.0%|
Stable Share Price: INVA is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: INVA's weekly volatility (5%) has been stable over the past year.
About the Company
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP.
Innoviva Fundamentals Summary
|INVA fundamental statistics|
Is INVA overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|INVA income statement (TTM)|
|Cost of Revenue||US$6.37m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||2.69|
|Net Profit Margin||47.30%|
How did INVA perform over the long term?See historical performance and comparison
Is Innoviva undervalued compared to its fair value and its price relative to the market?
Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: INVA ($16.29) is trading below our estimate of fair value ($199.04)
Significantly Below Fair Value: INVA is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: INVA is good value based on its PE Ratio (6.1x) compared to the US Pharmaceuticals industry average (20.1x).
PE vs Market: INVA is good value based on its PE Ratio (6.1x) compared to the US market (15.3x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate INVA's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: INVA is overvalued based on its PB Ratio (2.9x) compared to the US Pharmaceuticals industry average (1.8x).
How is Innoviva forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual revenue growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if INVA's forecast earnings growth is above the savings rate (1.9%).
Earnings vs Market: Insufficient data to determine if INVA's earnings are forecast to grow faster than the US market
High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: INVA's revenue is expected to decline over the next 3 years (-4.3% per year).
High Growth Revenue: INVA's revenue is forecast to decline over the next 3 years (-4.3% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: INVA's Return on Equity is forecast to be low in 3 years time (16.1%).
How has Innoviva performed over the past 5 years?
Past Performance Score3/6
Past Performance Score 3/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: INVA has high quality earnings.
Growing Profit Margin: INVA's current net profit margins (47.3%) are lower than last year (73.7%).
Past Earnings Growth Analysis
Earnings Trend: INVA's earnings have grown by 11.9% per year over the past 5 years.
Accelerating Growth: INVA's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: INVA had negative earnings growth (-25.9%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (16.9%).
Return on Equity
High ROE: INVA's Return on Equity (53.8%) is considered outstanding.
How is Innoviva's financial position?
Financial Health Score4/6
Financial Health Score 4/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: INVA's short term assets ($317.8M) exceed its short term liabilities ($109.2M).
Long Term Liabilities: INVA's short term assets ($317.8M) do not cover its long term liabilities ($446.0M).
Debt to Equity History and Analysis
Debt Level: INVA's net debt to equity ratio (58.3%) is considered high.
Reducing Debt: INVA had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Debt Coverage: INVA's debt is well covered by operating cash flow (70.1%).
Interest Coverage: INVA's interest payments on its debt are well covered by EBIT (24.7x coverage).
What is Innoviva current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate INVA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate INVA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if INVA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if INVA's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: INVA is not paying a notable dividend for the US market.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as INVA has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Pavel Raifeld (37 yo)
Mr. Pavel Raifeld, CFA, serves as Chief Executive Officer of Innoviva, Inc. since May 2020. He is a seasoned healthcare executive with a strong background in strategy, business development and corporate fi...
CEO Compensation Analysis
Compensation vs Market: Pavel's total compensation ($USD1.27M) is below average for companies of similar size in the US market ($USD3.94M).
Compensation vs Earnings: Pavel's compensation has been consistent with company performance over the past year.
Experienced Board: INVA's board of directors are considered experienced (4.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Innoviva, Inc.'s employee growth, exchange listings and data sources
- Name: Innoviva, Inc.
- Ticker: INVA
- Exchange: NasdaqGS
- Founded: 1996
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$1.135b
- Shares outstanding: 69.70m
- Website: https://www.inva.com
Number of Employees
- Innoviva, Inc.
- 1350 Old Bayshore Highway
- Suite 400
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/21 00:00|
|End of Day Share Price||2022/05/20 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.